• Overview
  • Eligibility
  • More info
  • Locations

Phase II Study of MGI-114 in Patients With Metastatic Breast Cancer (NCT00003796)

Phase II trial to study the effectiveness of irofulven in treating patients who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
  • Drug: irofulven
    Ages eligible for Study
    all
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    OBJECTIVES:

    I. Evaluate the response rate and time to treatment failure in patients with refractory metastatic adenocarcinoma of the breast treated with irofulven.

    II. Assess the qualitative and quantitative toxic effects of this drug in these patients.

    III. Determine the population pharmacokinetics and the pharmacokinetics-pharmacodynamic relationships of this drug in these patients.

    OUTLINE: This is a multicenter study.

    Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.

    1 locations

    United States (1)
    • University of Texas Health Science Center at San Antonio
      San Antonio, Texas, United States, 78229-3900
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 April, 1999
    Updated:
    07 February, 2013
    Participants:
    32
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!